60 results about "Allergic response" patented technology

Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis.

The present invention relates to the compound of formula

which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

Provided is an enteric preparation for preventing and curing hyperuricemia and gout. The employing essential component of the preparation is enteric capsules of uricase. The causes of the hyperuricemia and the gout are that uric acid is over generated and / or the uric acid is diminished in discharging, and metabolic diseases increasing the density of serum uric acid. About one third of the uric acid of the human body is defecated from intestinal canals, and the uric acid entering the canals still can be reabsorbed. When the hyperuricemia and the gout happen, the proportion of the uric acid defecated from the intestinal canals is increased. The uricase is capable of rapidly effectively dissociating the uric acid. The uricase of the enteric preparation after being orally taken is disintegrated in the intestinal canals and is diffused from blood into the uric acid of the intestinal canals, preventing the uric acid from reabsorbing, thereby reducing the density of the serum uric acid, achieving the purposes of preventing and curing the hyperuricemia and the gout. The oral uricase has the characteristics of non-absorbent property by the intestinal canals, keeping out of blood circulation, no producing of antibodies of organisms and allergic response, providing a new method for preventing and curing the hyperuricemia and the gout.

The invention relates to model systems for allergic conditions, and in particular to in vivo model systems in a large animal. The model systems of the invention are especially useful for providing large numbers of activated or non-activated eosinophils, for the discovery and evaluation of novel anti-inflammatory drug targets and for providing a model for the in vivo study of asthma and the effects of allergy treatments. In a preferred embodiment the animal is a sheep. In one embodiment, repeated infusion of house dust mite allergen (HDM) into the mammary gland is used to induce a specific allergic response, which is characterised by the recruitment of inflammatory cells, particularly eosinophils, into the mammary lumen; these cells can be harvested from peripheral blood and mammary lavage (MAL). In a second embodiment, the mammal is immunised with soluble antigen, for example by repeated subcutaneous immunisation, and then subjected to a single challenge with the same antigen administered directly to the lung.

The present invention discloses emulsified wax compositions having a wide range of uses, including as cosmetic, pharmaceutical and agricultural compositions, particularly for improving skin moisture, appearance, and wound healing, for the treatment of inflammation and allergic responses of the skin, and for preservation of agricultural fresh produce. The composition of the invention comprises an aqueous phase and at least one wax at a concentration of at least 5%, at least one fatty acid and at least one basic amino acid or a salt thereof.

The present invention is directed to materials and methods that may be used in diagnosing and/or characterizing allergies. More specifically, the specification describes methods and compositions for making and using a plurality of peptides having allergen epitopes that may be used in immunoassays e.g., microarray-based immunoassays to predict the severity of an allergic response.

An composition and related method that prevents, inhibits and/ or mitigates an allergic response by down regulating the production of IgE, down regulating the binding of IgE antibodies to receptors on cells, and/or inhibiting allergy mediators, for example, histamine, prostoglandin D₂, or luekotriene C₄ release. The composition comprises at least one of the following ingredients: luteolin from Perilla leaf or seed, Cinnamon, Kiwi, Picao preto, Hesperidin, Acerola cherry, Guaco, Holy Basil, Kakadu, Solamum, Rosmarinic acid, Tinospora and Aframomum. In one embodiment, the composition at least three different ingredients selected from Cinnamon, Acerola, Luteolin and Picao preto. Optionally, these ingredients can be combined with at least one of Aframomum, Rosmarinic acid, and Tinospora. The composition is administered with effective amounts to prevent, inhibit and/or mitigate allergic responses.

The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

The present invention relates to compounds of formulae IA and IB

wherein

• R¹ and R² are each independently lower alkyl or —(CH₂)_m—O-lower alkyl, or together with the N atom to which they are attached form a heterocyclic ring;
• R³ is hydrogen or lower alkyl;
• R⁴ is lower alkyl; hetaryl is 3H-imidazole-2,4-diyl or 1H-pyrazole-1,4-diyl; n is 1 or 2; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.

A method and kit for the sequential early introduction to an infant of at least two allergens to decrease the infant's risk for developing allergies, the method involving administering an initial lower, exposure dose of a first allergen for a day or two, followed by administering a higher maintenance dose of the first allergen for several days, followed by administering the maintenance dose of the first allergen and an initial lower, exposure dose of a second allergen for a day or two, followed by administering the higher maintenance dose of the first allergen and a higher maintenance does of the second allergen for several days. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula or to mother's milk. Alternatively, the allergens can already be provided in baby formula, or in other foods such as snack bars, cookies, or gels.

The invention relates to an injection medicament for treating hyperthyroid, which comprises the following components by weight part: 2 to 5 milligrams of dexamethasone injection, 0.5 to 1 milligram of octreotide injection, and 10 to 20 milligrams of ciclosporin A. Immune preparations such as the dexamethasone injection, the octreotide injection, the ciclosporin A and the like are adopted for treating the hyperthyroid by locally injecting the thyroid, the volume of the tumid thyroid is remarkably shrunk, and the function of the thyroid basically recovers within two months, so the injection medicament has remarkable curative effect, and can remarkably improve the remission rate of hyperthyroid and reduce the rate of relapse. Serious abnormal change, hypothyroidism and parathyroid hypofunction are not caused, and laryngeal recurrent nerve injury is also not caused. Through more than 580 cases of clinical therapy in related hospitals, the volume of the tumid thyroid is remarkably shrunk after therapy, clinical symptoms disappear, allergic response and complications are not caused, the effective percentage is nearly 100 percent, and the cure rate is as high as 98 percent.

The present invention recognizes that current clinical laboratory testing methods for multiparametric single cell analysis are limited to analysis of intact live cells, and are insufficient for identification of signaling activation profile defining certain cell types, including but not limited to neoplastic and immunologically activated cell subsets. One aspect of the present invention generally relates to marker selection in panels to include proteins routinely assessed in standard FCM, while preferably also incorporating markers for surface receptor proteins within activated signaling cascades. A further aspect of the present invention generally relates to panel design for the following indications in neoplastic and non-neoplastic clinical applications as examples of the technology: (a) identification of CML progenitor cell subsets in the setting of disease recurrence after treatment discontinuation or relapse due to treatment resistance, and (b) characterization of activated basophils to predict the severity of an allergic response. Another aspect of the present invention generally relates to methods to measure levels of surface and IC biomarkers in separate or combined assays for robust characterization of each or select cell compartment, and data analysis based on results from each or all method(s) used for optimal detection of the markers. A further aspect of the present invention generally relates to the identification and profiling of cell subpopulations based on analysis of surface markers including those associated with lineage and maturation of cell types and receptor proteins, and the corresponding IC phosphoproteins including those in activated signaling cascades to predict certain disease states or response to treatment.

A topical pharmaceutical composition for treating a skin disorder selected from the group consisting of Herpes viral infection, Varicella viral infection, rash, insect bites, jellyfish stings, burns, psoriasis, itching, skin allergic response, skin lesions as a result of drug or medical treatment side effects or complications, and hypopigmantation. The composition comprises a peptide of the formula pGLU-X—Y—Z, where X, Y and Z are amino acids, with or without an alkyl group, and a pharmaceutically acceptable excipient.

This invention relates to the purification, cloning and characterization of a novel gene, Gab2. In response to extracellular stimuli (e.g., cyokines, growth factors, hormones and antigens), Gab2 binds several signal relay molecules, including the protein-tyrosine phosphatase SHP-2 and phosphatidylinositol-3-OH kinase (PI-3K), which results in the initiation of multiple signaling cascades. Gab2 nucleic acid molecules, peptides, vectors, host cells, probes, antibodies, knockout and transgenic animals are provided. The invention also relates to methods of diagnosis, prevention and treatment of Gab2-mediated conditions such as allergic responses, neoplastic disorders and immune disorders. The invention further relates to diagnostic kits for disorders associated with altered Gab2 expression.

The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.

The present invention relates to phorbol esters from the seeds of Aquilaria malaccensis by a series of chromatographic processes, and compositions containing these congeners for the treatment or prevention of allergic responses. Furthermore, compositions are provided which comprise these phorbol esters in combination with at least one to assess the effects for preventing or treating allergies.